---
title: "Top 10 HK Stock Losers (3.20)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279909679.md"
description: "XUANZHUBIO-B(02575) fell 13.72%, with a trading turnover 72.3 Million HKD, and a year-to-date fell 39%. PAX GLOBAL(00327) fell 13.15%, with a trading turnover 76.7 Million HKD, and a year-to-date fell 26.7%. JINHAI MED TECH(02225) fell 12.12%, with a trading turnover 19.0 Million HKD, and a year-to-date rose 62.4%."
datetime: "2026-03-20T08:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279909679.md)
  - [en](https://longbridge.com/en/news/279909679.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279909679.md)
---

# Top 10 HK Stock Losers (3.20)

Hang Seng Index has fell 0.88%, with a year-to-date fell 1.4%; Hang Seng TECH Index has fell 2.48%, with a year-to-date fell 11.7%.

XUANZHUBIO-B(02575) fell 13.72%, with a trading turnover 72.3 Million HKD, and a year-to-date fell 39%.

PAX GLOBAL(00327) fell 13.15%, with a trading turnover 76.7 Million HKD, and a year-to-date fell 26.7%.

JINHAI MED TECH(02225) fell 12.12%, with a trading turnover 19.0 Million HKD, and a year-to-date rose 62.4%.

### Related Stocks

- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)
- [00327.HK](https://longbridge.com/en/quote/00327.HK.md)
- [02225.HK](https://longbridge.com/en/quote/02225.HK.md)
- [02650.HK](https://longbridge.com/en/quote/02650.HK.md)
- [06090.HK](https://longbridge.com/en/quote/06090.HK.md)
- [09860.HK](https://longbridge.com/en/quote/09860.HK.md)
- [01907.HK](https://longbridge.com/en/quote/01907.HK.md)
- [03928.HK](https://longbridge.com/en/quote/03928.HK.md)
- [00861.HK](https://longbridge.com/en/quote/00861.HK.md)
- [03636.HK](https://longbridge.com/en/quote/03636.HK.md)

## Related News & Research

- [Shanghai Zhida Wins Full Shareholder Backing for AGM Resolutions, Capital Mandates and Governance Changes](https://longbridge.com/en/news/284029110.md)
- [Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan](https://longbridge.com/en/news/282442087.md)
- [Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision](https://longbridge.com/en/news/279271433.md)
- [Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib](https://longbridge.com/en/news/283291980.md)
- [Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology](https://longbridge.com/en/news/280309450.md)